Our Principal, Pauli Wong, was invited to be one of the guest speakers at the “GBA Innovative MedTech Development Luncheon” on Wednesday (15 February) at HKSTP, sharing her insights on the unique IP challenges MedTech and healthcare innovations face in the GBA and China. The event was co-hosted by Society for Innovative Healthcare Hong Kong, Hong Kong College of Health Service Executives, GBA Medical Professional Study Tour, Doctors Think Tank Academy and CycloCorp.




Our Past Events

Eagle IP Celebrates 20th Anniversary, Reflecting on Two Decades of Excellence

21 May 2025

Eagle IP is Coming Back to LSPN in Boston!

24 April 2025

AIPLA Women in IP Global Networking Event in Hong Kong

3 April 2025

Talk at Hong Kong Christian Service

31 October 2024

Talk for HKUST Entrepreneurship 101 Training Program

31 October 2024

IP Training Programme on patent commercialization and technology transfer

8 October 2024

Recommended Insights

How Far Can an Employer Reach to Own Employee-made “Service Inventions”?

30 July 2020
2019 China’s Top 50 Representative IP Cases Shenzhen Weibang Technology Co. Ltd v. Li Jianyi & Shenzhen Yuancheng Intelligence Equipment Co. Ltd (2019最高法民申6342号) Each year in China there are hundreds of disputes over patent ownership.  A significant part of them are related to “Service Inventions”, which are defined in Article 6 of the Chinese Patent […]
Read more >

China’s Supreme People’s Court (SPC) Hands Down First Patent Linkage Appeal Decision

21 September 2022
China has been implementing a plethora of new laws and measures that are particularly favorable to drug companies, such as patent term extension and patent linkage.  Details of the new implementation measures for patent linkage (technically “early dispute resolution mechanisms for drug patents”) came into effect on July 4, 2021. At around the same time, […]
Read more >

Beijing IP Court Reverses CNIPA Decision and Upholds Ozempic® semaglutide patent in China as VALID based on Novo Nordisk’s Post Filing Data

27 June 2024
Recently, all eyes have been on China as the fundamental patent covering semaglutide, the active ingredient in Ozempic® and Wegovy®, will expire on March 20, 2026. It goes without saying that generics are ramping up bigtime in China (and also around the world), preparing to manufacture and sell this blockbuster drug to one of the […]
Read more >

Major and Exciting Changes to China’s Patent Law [Fourth Amendment to China's Patent Law]

20 February 2019
Major changes are on the horizon for China’s Patent Law, which will see an overhaul in many areas as early as this year (2019). On January 4, 2019, the National People’s Congress in China published the latest draft of the Fourth Amendment to China’s Patent Law. Several draft amendments have been released for public comment […]
Read more >
Top crossarrow-right